1. Volume 11, Issue 3, Pages 266-274 (March 2010)
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601) 
Prof John MS Bartlett, PhD, Alison F Munro, MSc, Janet A Dunn, PhD, Christopher McConkey, MSc, Sarah Jordan, MSc, Prof Chris J Twelves, MD, Prof David A Cameron, MD, Jeremy Thomas, MBBS, Fiona M Campbell, MSc, Daniel W Rea, PhD, Elena Provenzano, MBBS, Prof Carlos Caldas, FMedSci, Paul Pharoah, BMBCh, Louise Hiller, PhD, Helena Earl, MBBS, Prof Christopher J Poole, MBBChir 
The Lancet Oncology 
Volume 11, Issue 3, Pages (March 2010)
DOI: /S (10)
Copyright © 2010 Elsevier Ltd Terms and Conditions

2. Figure 1
Hazard ratio (HR) plot for treatment-by-marker interactions for relapse-free survival
Ch17CEP=chromosome 17 centromere enumeration probe. IHC=immunohistochemistry. ECMF=epirubicin, cyclophosphamide, methotrexate, fluorouracil. CMF=cyclophosphamide, methotrexate, fluorouracil.
The Lancet Oncology  , DOI: ( /S (10) )
Copyright © 2010 Elsevier Ltd Terms and Conditions

3. Figure 2
Hazard ratio (HR) plot for treatment-by-marker interactions for overall survival
Ch17CEP=chromosome 17 centromere enumeration probe. IHC=immunohistochemistry. ECMF=epirubicin, cyclophosphamide, methotrexate, fluorouracil. CMF=cyclophosphamide, methotrexate, fluorouracil.
The Lancet Oncology  , DOI: ( /S (10) )
Copyright © 2010 Elsevier Ltd Terms and Conditions

4. Figure 3
Relapse-free and overall survival for patients with tumours exhibiting Ch17CEP duplication and Ch17CEP normal
(A) Relapse-free survival for ChCEP17 normal. (B) Relapse-free survival for ChCEP17 duplication. (C) Overall survival for ChCEP17 normal. (D) Overall survival for ChCEP17 duplication. Ch17CEP=chromosome 17 centromere enumeration probe. ECMF=epirubicin, cyclophosphamide, methotrexate, fluorouracil. CMF=cyclophosphamide, methotrexate, fluorouracil.
The Lancet Oncology  , DOI: ( /S (10) )
Copyright © 2010 Elsevier Ltd Terms and Conditions

5. Figure 4
Hazard ratio (HR) plot for treatment by marker interactions for relapse-free survival stratified by Ch17CEP and HER2/TOP2A
Ch17CEP=chromosome 17 centromere enumeration probe. ECMF=epirubicin, cyclophosphamide, methotrexate, fluorouracil. CMF=cyclophosphamide, methotrexate, fluorouracil.
The Lancet Oncology  , DOI: ( /S (10) )
Copyright © 2010 Elsevier Ltd Terms and Conditions